|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.325 AUD | +4.26% |
|
-5.67% | -14.34% |
| 02-06 | ASX Biggest Losers | MT |
| 01-29 | Mesoblast to Start Site Enrollment in Pivotal Trial for Cell Therapy Label Extension; Shares Fall 4% | MT |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
 | 4 | |||||||
| 23 | |||||||
| 24 | |||||||
| 22 | |||||||
| 20 | |||||||
| 19 | |||||||
| 12 | |||||||
| 15 | |||||||
| 22 | |||||||
| 16 | |||||||
| 16 | |||||||
| 14 | |||||||
| 12 | |||||||
| 12 | |||||||
| Average | 16 | |||||||
| Weighted average by Cap. | 19 |
- Stock Market
- Equities
- MSB Stock
- Sector Mesoblast Limited
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition